Lab-In-A-Pocket

anvajo GmbH is an innovative life science and medtech company from Dresden that has set itself the goal of providing access to laboratory diagnostics for everyone, at any time and worldwide. The company develops and distributes point-of-care devices that analyze liquids quickly, cost-effectively and reliably. At the heart of this technology are digital holographic microscopy and a compact spectrometer, which together form the basis for the so-called fluidlabs. One of the products, the first generation fluidlab, is already being used in various areas of medical diagnostics as well as in research and industry. It offers a cost-effective and portable solution for carrying out precise analyses - and is attracting growing interest in the target sectors. The anvajo team is driven by the development of cutting-edge technology for medicine and research. At the heart of anvajo's fluidlabs are the compact spectrometer and digital holographic microscopy (DHM). anvajo is a pioneer in this field: never before has DHM been possible in this quality and at this handy size. In combination with self-learning algorithms and continuous software development, the fluidlabs enable new applications for the detection, monitoring and treatment of diseases - and simplify work in research laboratories.

The fluidlab R-300 combines a fully-fledged spectrometer with an automated cell counter in a small, portable device to perform a wide range of medical technology analyses. Developed specifically for veterinary diagnostics, the vet fluidlab's quantitative phase diagnostic technology enables automated microscopy of non-centrifuged urine on site - helping veterinarians to make immediate and more accurate diagnoses and treatments.
anvajo is also impressing the market with its latest products for human medicine: the health fluidlab 1 with its automated urine microscopy makes the everyday work of doctors easier and, as a digital access to laboratory diagnostics, is an important building block in the digitalization of the healthcare system. It can also close gaps in care in regions that previously did not have a well-developed medical infrastructure.

The second generation of the fluidlab platform was also launched on the market with a partner company at the beginning of 2024. "Our vision is better healthcare in which diseases can be detected more quickly, therapies can be developed more efficiently and their progress can be tracked more accurately," explains Stefan Fraedrich, founder and CEO of anvajo. "With the new financing, we will be able to intensify the further development of our products and open up additional markets for our fluidlab platform."